Companies don’t plan to fail when it comes to recruitment, but many fail to plan. What happens if your marketing director resigns? A recruiting plan gives your organization the confidence in knowing that whatever happens, there is a process in…
BUSINESS
Astellas to Divest Antifungal Micafungin to Sandoz for Up to US$75 Million Upfront
Astellas Pharma said on January 24 that it has struck an agreement to transfer the worldwide product rights for its antifungal agent micafungin, known with the trade names of Mycamine or Funguard, to Sandoz. The asset purchase pact, which also…
To read the full story
BUSINESS
- Astellas EVP Okamura to Become CEO in April
February 6, 2023
- Mitsubishi Chemical Calls It Quit for Medicago, COVID Jab
February 6, 2023
- Takeda Logs Double-Digit Growth, Led by Core Products and Weaker Yen
February 3, 2023
- Nobelpharma’s Nobelzin Granules Now Available, 2 Years after Approval
February 3, 2023
- Takeda Joins Pilot Study of Robotic Drug Delivery Service in Tokyo
February 3, 2023
Is policy intervention necessary for Japanese drug makers reliant on off-patent brand-name medicines? Many members of the health ministry’s key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
The Liberal Democratic Party (LDP) will wrap up its discussions on the FY2023 tax reform plan within a few days. Some provisions of the R&D tax credit system, which allow drug makers to deduct a portion of R&D expenses from…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…